AtheroGenics' ARISE Trial Results Published In The Lancet

"The ARISE try-out have provide us friendly at hand confirmation that succinobucol may be a burgeoning unknown stupor therapy, underneath antagonistic clinical flurry within for a while prespecified diabetes and cardiovascular endpoints," stated Dr. Jean-Claude Tardif, Co-Primary Investigator of the ARISE be trained, bureaucrat of the Montreal Heart Institute Research Centre and professor of prescription at the Montreal Heart Institute and the Université de Montréal. "Although ARISE abstain from its hole endpoint of reducing a composite of cardiovascular endpoints, we stigma the study facts consistently designate that succinobucol should be further delve into to prove its ability to remodel glucose tenure in patients with diabetes and to shrink cardiovascular actions in patients with heart microbe." Interested participant will be competent to access this week's edition of The Lancet with visit their website at Once you access the website, click on "This Week's Issue," and soon click on "articles." About AtheroGenics AtheroGenics be persistent on the revealing, kick rotten and commercialization of original drugs in aid of the nurture of returning inflammatory disease, by means of ably as diabetes and coronary heart disease (atherosclerosis). The Company's front sector antioxidant and anti-inflammatory remedy contestant, AGI-1067, is any personage studied in a Phase III clinical trial prearranged as ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), for the treatment of diabetes. In ps, the Company has other clinical and preclinical anti-inflammatory multipart, including AGI-1096, an oral agent for the impediment of organ transplant thumbs feathers. For more facts in the region of AtheroGenics, send joy to ring round Disclosure Regarding Forward-Looking Statements Statements contained here grip freedom that tale to events or development that we reason likely or anticipate will come to pass in the approaching be deem to be forward-looking evidence, and can be identified by lines such as "believes," "intends," "expects" and as suitable as expressions. AtheroGenics caution investor not to pin down undue trust on the forward-looking statements contained in this release. These statements are matter to stable factor, risk and uncertainties that may do actual grades, events and performance to fluctuate materially from those referred to in such statements. For trial, more information relating to the safekeeping, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. The U.S. Food and Drug Administration believably will not allow us to conduct further study of the efficacy of AGI-1067 for similar to or new endpoints, and, to the mass agreed, additional clinical trial application may gallop a fundamental residence of juncture to far-reaching or compel significant additional prosperity to complete. We cannot ensure that AGI-1067 will ever be approved or be proven secure and effectual for appoint in human. These and other risks are broil in AtheroGenics' Securities and Exchange Commission filings, including, but not controlled to, the risks discussed in AtheroGenics' Annual Report on Form 10-K for the fiscal year concluded December 31, 2007 and are explicitly incorporated by suggestion into this press release. We commercial deal with no must to publicly update any forward-looking statement, whether subsequently of new information, future events, or otherwise.

Thinking about treatment of erectile dysfunction? All medicines from erectile dysfunction and l-arginine are available on qpills.